Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 1, January, p. 59–65

doi: 10.17219/acem/76253

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Expression of caspase 1 and histomorphology of lung after cladribine treatment

Marta Lis-Sochocka1,B,C,D, Patrycja Chylińska-Wrzos1,B,C,D, Ewelina Wawryk-Gawda1,B,C,D, Barbara Jodłowska-Jędrych1,A,E,F

1 Department of Histology and Embryology with Experimental Cytology Unit, Medical University of Lublin, Poland

Abstract

Background. Cladribine is a useful immunosuppressive drug for the treatment of autoimmune diseases, leukemias and multiple sclerosis (MS). Despite the drug having low toxicity, side effects have been reported connected with myelosuppression, neutropenia and severe anemia.
Objectives. The objective of this study was to investigate the influence of cladribine on lung pathomorphology and the expression of caspase 1 using immunohistochemistry method.
Material and Methods. The study was conducted on Wistar rats, which were divided into a control group (C) and an experimental group (E). In group C, the rats were given a 0.9% NaCl solution by a subcutaneous injection, at the same dose as the dose of drug used in the experiment. In group E, the animals received cladribine at a dose of 0.07 mg/kg/24 h by a subcutaneous injection. The animals were decapitated 24 h following the last dose. To detect collagen deposition, we utilized Masson’s trichrome staining. To evaluate the intensity of the inflammatory process in the lung, an immunohistochemistry reaction was carried out with the use of caspase 1.
Results. In group E, we observed an increase in the thickness of space between the alveoli. A statistically significant (p < 0.017243) difference between the thicknesses of the interalveolar septum was seen between the research groups. In E group, we observed regions with collagen deposition, alveolar epithelial cell hyperplasia, hyperemia and inflammatory cell infiltration. Caspase 1 activity was higher in group E. The immunohistochemical reaction with caspase 1 was positive in 49% of all the interalveolar cells in group E; however, in group C about 13% of the interalveolar cell showed positive immunohistochemistry (IHC) response.
Conclusion. Cladribine-based therapy might have negative influence on lung morphology. The interstitial changes in the lung tissue suggest that cladribine is a drug that may be the cause of drug-induced lung disease and may lead to several respiratory disorders.

Key words

inflammation, lung, caspase 1, cladribine

References (39)

  1. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63–74. doi: 10.2174/1874306401206010063
  2. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: Not just another purine analogue? Expert Opin Investing Drugs. 2009;18(8):1169–1181.
  3. Leist TP, Weissert R. Cladribine: Mode of action and implications for treatment of multiple sclerosis. Clin Neuropharm. 2011;34:28–35.
  4. Hartung HP, Aktas O, Kieseier B, Comi G. Development of oral cladribine for the treatment of multiple sclerosis. J Neurol. 2010;257:163–170.
  5. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation. Curr Med Res Opin. 2007;23(11):2667–2676.
  6. Warnke C, Leussink VI, Goebels N, et al. Cladribine as a therapeutic option in multiple sclerosis. Clin Immunol. 2012;142:68–75.
  7. Kobelska-Dubiel N, Górnaś M. Powikłania chemioterapii. http://www.amgen.pl/produkty/public/pdf/Powikania_po_chemioterapii.pdf. Accessed June 11, 2012.
  8. Jędrych M, Wawryk-Gawda E, Jodłowska-Jędrych B, Chylińska-Wrzos P, Jasiński L. Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovarian surface epithelial cells of cladribine-treated rats. Protoplasma. 2013;250:1025–1034. doi: 10.1007/s00709-012-0461-z
  9. Wawryk-Gawda E, Chylińska-Wrzos P, Lis-Sochocka M, et al. P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 2014; 251:525–533. doi: 10.1007/s00709-013-0548-1
  10. Wawryk-Gawda E, Chylińska-Wrzos P, Lis-Sochocka M, Bulak K, Jodłowska-Jędrych B. Intrinsic apoptosis pathway in fallopian tube epithelial cells induced by cladribine. Sci World J. 2014. doi.org/10.1155/2014/928036
  11. Chylinska-Wrzos P, Wawryk-Gawda E, Lis-Sochocka M, et al. The intrinsic or the extrinsic pathways of apoptosis in the epidermis after cladribine application? J Biomed Sci Eng. 2013;6:265–272. doi.org/10.4236/jbise.2013.63033
  12. Chylińska-Wrzos P, Lis-Sochocka M, Wawryk-Gawda E, et al. Expression of p53 protein and the histomorphological view of epidermis in experimental animals after cladribine application. IJVR. 2014; 15(3,48):198–205.
  13. Fatima N, Toscano MP, Hunter SB, Cohen C. Controversial role of Epsein-Barr virus in multiple sclerosis. Appl Immunohistochem Mol Morphol. 2011;19(3):246–252. doi: 10.1097/PAI.0b013e3181fcf3b4
  14. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol. 2009;22:226–232.
  15. Kasper LH, Shoemaker J. Multiple sclerosis immunology. The healthy immune system vs the MS immune system. Neurology. 2010;74(1):S2–S8.
  16. Losy J. Patogeneza oraz aktualne kryteria diagnostyczne stwardnienia rozsianego. Neurologia i Psychiatria. 2004;4:53–56.
  17. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis. recent advances and future prospects. Drugs. 2008;68(17):2445–2468.
  18. Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics. Maximizing efficacy of therapy. Neurology. 2010;74(1):S62–S69.
  19. Coyle PK. Existing therapies for multiple sclerosis offer proven efficacy and safety. Curr Opin Neurol. 2009;22:S4–S9.
  20. Montalban X. Multiple sclerosis therapy: Historical and future perspectives. Curr Opin Neurol. 2009;22:S1–S3.
  21. Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs. 2009;18(7):985–989.
  22. Slavin A, Kelly-Modis L, Labadia M, Ryan K, Brown ML. Pathogenetic mechanism and experimental models of multiple sclerosis. Autoimmunity.2010;43(7):504–513.
  23. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology. 2000;55:1714–1718.
  24. Rice GP, Fillipi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54(5):1145–1155.
  25. Wawryk-Gawda E, Chylińska-Wrzos P, Jodłowska-Jędrych B, Lis-Sochocka M. Use of selected purine analogs in neoplastic and autoimmune diseases. Annales UMCS, Sectio DDD. Pharmacia. 2011; 24(4,3):29–47.
  26. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: Mechanism of action and clinical activity. Curr Med Chem. 2006;13:3165–3189.
  27. Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules. 2009;14:1183–1226.
  28. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17: 372–379. doi:10.1093/annonc/mdj057
  29. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. Cladribine (2-CdA) given as subcutaneous bolus injections is active in pretreated Waldenstrom macroglobulinaemia. Br J Haematol. 1997;99:358–363.
  30. Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2’-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83:356–363. doi 10.1007/s00277-004-0858-7
  31. Montillo M, Tedeschi A, O’Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 2003;97(1):114–120.
  32. Okawa Y, Shimada T, Nagasaki E, Nozato A, Mizoroki F, Kobayashi M. Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma. Jpn J Clin Oncol. 2006;47(7):650–655.
  33. Fridrik MA, Jager G, Kienzer HR, et al. Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) – 2 h infusion for 5 days – as first-line treatment for advanced low grade Non-Hodgkin’s lymphoma. Eur J Cancer. 1998;34(10):1560–1564.
  34. Feenstra JF, Hickey BP, Blackwell EA. Acute respiratory failure associated with cladribine pneumonitis. Int Med J. 2004;34(9–10):583–584.
  35. Broz P, von Moltke J, Jones JW, Vance RE, Monack DM. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe. 2010;8:471–483.
  36. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27: 6194–6206.
  37. Park HH. Structural features of Caspase-activating complexes. Int J Mol Sci. 2012;13:4807-4818. doi: 10.3390/ijms13044807
  38. Brough D, Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1βis cytosolic and precedes cell death. J Cell Sci. 2007;120: 772–781. doi: 10.1242/jcs.03377
  39. Cui K, Kou JQ, Gu JH, et al. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress. BMC Complement Altern Med. 2014;14:461. doi: 10.1186/1472-6882-14-461
© Wroclaw Medical University